

Colcrys

This solicitation is for the acquisition for Colcrys, a covered drug sourced from a non-Trade Agreement Act (TAA) country, for all strengths and sizes listed in the schedule of supplies pursuant to Federal Acquisition Regulation (FAR) Part 25. Other strengths and sizes may be added to the subsequent contract by mutual agreement between the awardee and the Government through execution of a bilateral modification of the contract. Awarded strengths and size may also be deleted from subsequent contract if their non-TAA status changes.

This product is a branded drug and the requirement of Public Law 102-585, Veterans Healthcare Act of 1992, Section 603 shall apply to the price proposed on this solicitation for the Department of Veterans Affairs (VA), including certain State Veterans Homes (SVH), Federal Healthcare Center (FHCC), Department of Defense (DoD), Indian Health Services (IHS) and the Bureau of Prisons (BOP). Therefore awarded prices shall not exceed the annually established Federal Ceiling Price (FCP) plus the 0.5% Cost Recovery Fee (CRF) for VA, DoD, IHS and BOP. Please note that although prices are being requested for the base year and all four option years, the annually established FCP plus the CRF will govern for subsequent option years. The contract will be modified bilaterally to reflect the annually established FCP plus the CRF in effect for each subsequent option year.

If a pre-priced option year price is lower than the annually established FCP plus the 0.5% CRF, the contractor may choose to extend the lower price for each subsequent option year and the contract will be modified unilaterally to reflect the lower price.

To be considered for award, offeror shall propose a price for line items 1 and 2 for the base year and all four option years. Award will be made in the aggregate for line items 1 and 2 for the base year and all four option years.

Offered prices must include the Cost Recovery Fee of 0.5% as outlined in the scope of the contract.